Variant · Snv

PIK3CA E545A

CI-VAR-00000775Explore in graph →NP_006209.2:p.Glu545AlaNM_006218.3:c.1634A>CClinVar 13659 CIViC 882 rs121913274

Curated evidence

Evidence by cancer (4 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–4 of 4 evidence items across 3 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma1
PIK3CA E545A	PI103	Predictive	D	Supports Sensitivity Response	—	submitted	EID2052 In H460, a gefitinib-resistant NSCLC cell line that harbors PIK3CA mutations, the dual PI3Kalpha/mTOR inhibitor PI103 reduced cell growth and increased the expression of the tumor suppressor p53 compa… (full text at CIViC) PMID 19513541 · Zou et al., 2009 · Open in CIViC	civic
Malignant Breast Neoplasm2
PIK3CA E545K OR PIK3CA E545A OR PIK3CA E545G OR PIK3CA E545D	Alpelisib + FulvestrantCombination	Predictive	A	Supports Sensitivity Response	4	accepted	EID7468 In a phase 3 trial, 572 patients with hormone receptor positive, HER2 receptor negative advanced breast cancer who previously received endocrine therapy were allocated to alpelisib plus fulvestrant or…

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
13659	Pathogenic	criteria provided, multiple submitters, no conflicts	2	Hepatocellular carcinoma; Ovarian neoplasm; Abnormal cardiovascular system morphology; Dysembryoplastic neuroepithelial tumor; Neoplasm; Primary central nervous system lymphoma; PIK3CA related overgrowth syndrome	somatic	7	Aug 01, 2025